1. Home
  2. BMBL vs TERN Comparison

BMBL vs TERN Comparison

Compare BMBL & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMBL
  • TERN
  • Stock Information
  • Founded
  • BMBL 2014
  • TERN 2017
  • Country
  • BMBL United States
  • TERN United States
  • Employees
  • BMBL N/A
  • TERN N/A
  • Industry
  • BMBL Computer Software: Prepackaged Software
  • TERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • BMBL Technology
  • TERN Health Care
  • Exchange
  • BMBL Nasdaq
  • TERN Nasdaq
  • Market Cap
  • BMBL 756.3M
  • TERN 811.4M
  • IPO Year
  • BMBL 2021
  • TERN 2021
  • Fundamental
  • Price
  • BMBL $6.65
  • TERN $8.27
  • Analyst Decision
  • BMBL Buy
  • TERN Strong Buy
  • Analyst Count
  • BMBL 17
  • TERN 5
  • Target Price
  • BMBL $8.61
  • TERN $15.90
  • AVG Volume (30 Days)
  • BMBL 2.7M
  • TERN 3.7M
  • Earning Date
  • BMBL 11-05-2024
  • TERN 11-12-2024
  • Dividend Yield
  • BMBL N/A
  • TERN N/A
  • EPS Growth
  • BMBL N/A
  • TERN N/A
  • EPS
  • BMBL 0.31
  • TERN N/A
  • Revenue
  • BMBL $1,085,537,000.00
  • TERN N/A
  • Revenue This Year
  • BMBL $3.63
  • TERN N/A
  • Revenue Next Year
  • BMBL $0.37
  • TERN N/A
  • P/E Ratio
  • BMBL $21.53
  • TERN N/A
  • Revenue Growth
  • BMBL 11.11
  • TERN N/A
  • 52 Week Low
  • BMBL $4.80
  • TERN $3.26
  • 52 Week High
  • BMBL $15.90
  • TERN $11.40
  • Technical
  • Relative Strength Index (RSI)
  • BMBL 53.09
  • TERN 44.79
  • Support Level
  • BMBL $6.28
  • TERN $7.82
  • Resistance Level
  • BMBL $6.67
  • TERN $9.00
  • Average True Range (ATR)
  • BMBL 0.28
  • TERN 0.58
  • MACD
  • BMBL 0.09
  • TERN -0.22
  • Stochastic Oscillator
  • BMBL 81.77
  • TERN 15.63

About BMBL Bumble Inc.

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect.

About TERN Terns Pharmaceuticals Inc.

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

Share on Social Networks: